menu

FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

    Released May 30, 2017.

Facebook Comments

Recommended
Details
Comments
  • Overview

    The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

    Released May 30, 2017.

Facebook Comments

Schedule28 Mar 2024